Thyroid eye disease can make your eyes feel gritty, look swollen, refuse to point in the same direction, or behave as though they have developed strong opinions about closing at bedtime. Fortunately, treatment has advanced well beyond simply waiting for the inflammation to settle.
Also called TED, Graves’ eye disease, Graves’ ophthalmopathy, or thyroid-associated orbitopathy, thyroid eye disease is an autoimmune condition affecting the muscles, connective tissues, and fat around the eyes. Treatment depends on whether the condition is active or stable, how severely it affects vision and daily life, and which symptoms matter most to the person receiving care.
Medical note: Sudden vision loss, reduced color vision, a dark or blurred area in the visual field, severe eye pain, or an inability to close the eyelids requires urgent evaluation. This article provides general education and is not a substitute for individualized medical care.
How Do Doctors Choose a Thyroid Eye Disease Treatment?
There is no single treatment plan that fits every case of thyroid eye disease. Before recommending therapy, an ophthalmologist or orbital specialist usually evaluates two major factors: disease activity and disease severity.
Active versus inactive thyroid eye disease
During the active phase, immune-driven inflammation causes changing symptoms such as redness, pain, eyelid swelling, bulging eyes, and worsening double vision. This phase may continue for many months and, in some people, longer than a year.
During the inactive or stable phase, inflammation has largely settled. However, stretched eyelids, eye prominence, scarring of the eye muscles, or double vision may remain. Anti-inflammatory medication is generally less useful once these structural changes have stabilized, so rehabilitative surgery becomes more relevant.
Mild, moderate, severe, or sight-threatening disease
Mild TED may involve dryness, tearing, light sensitivity, or minor swelling without major effects on vision. Moderate-to-severe TED can cause obvious eye bulging, persistent inflammation, restricted eye movement, troublesome double vision, and meaningful changes in appearance or daily function.
Sight-threatening TED is less common but is a medical emergency. It may involve compression of the optic nerve, severe corneal exposure, corneal breakdown, or displacement of the eye from its normal position.
Does Treating the Thyroid Cure Thyroid Eye Disease?
Controlling thyroid hormone levels is essential, but it does not automatically switch off thyroid eye disease. The thyroid gland and the tissues around the eyes are separate targets of the autoimmune process. Think of them as two rooms affected by the same faulty fire alarm: fixing the alarm in one room does not guarantee silence in the other.
Doctors generally aim to keep thyroid hormone levels stable and within the recommended range because both overactive and underactive thyroid function can complicate TED. Treatment for Graves’ hyperthyroidism may involve antithyroid medication, radioactive iodine, or thyroid surgery.
Radioactive iodine can sometimes worsen existing eye disease, particularly in people who smoke or have active TED. In selected cases, a clinician may prescribe corticosteroids around the time of radioactive iodine treatment to reduce that risk. The safest thyroid treatment should be chosen collaboratively by the patient, endocrinologist, and eye specialist.
How Is Mild Thyroid Eye Disease Treated?
Mild symptoms often respond to supportive care while the disease is monitored. “Supportive” does not mean unimportant. A dry, exposed cornea can make every blink feel like someone sprinkled artisanal gravel under the eyelid.
Artificial tears, gels, and ointments
Preservative-free artificial tears can reduce dryness, burning, and grittiness during the day. Thicker gels or lubricating ointments may be useful at bedtime, especially when the eyelids do not fully close. A clinician may also recommend a moisture chamber or a safe method of gently closing the eyelids overnight.
Practical symptom relief
- Wear wraparound sunglasses to reduce light sensitivity, wind exposure, and irritation.
- Sleep with the head elevated to help decrease morning eyelid puffiness.
- Use cool compresses for temporary comfort.
- Ask about prism lenses if double vision interferes with reading, driving, or working.
- Review contact lens use with an eye care professional if dryness or exposure has worsened.
Smoking cessation
Stopping smoking is one of the most important steps a person with TED can take. Smoking is strongly associated with more severe disease, poorer treatment response, and greater risk of worsening after radioactive iodine. Avoiding secondhand smoke is also sensible. Quitting is difficult, so counseling, medication, nicotine-replacement strategies, and structured support may be more effective than relying on willpower and an increasingly judgmental refrigerator magnet.
Is selenium helpful?
Selenium supplementation may help selected people with mild, active TED, particularly in areas where selenium intake is low. It is not a universal cure and should not be taken in unlimited quantities. Excess selenium can cause nausea, brittle nails, hair loss, nerve symptoms, and a garlic-like breath odor that no mint deserves to battle. Ask a clinician whether supplementation is appropriate and what dose is safe.
How Is Active Moderate-to-Severe TED Treated?
When inflammation, eye prominence, double vision, pain, or changes in appearance significantly affect daily life, systemic treatment may be appropriate. The choice depends on medical history, access, insurance coverage, treatment goals, and which feature of TED is causing the greatest burden.
Intravenous or oral corticosteroids
Corticosteroids reduce inflammation and may improve redness, swelling, pain, and disease activity. Intravenous methylprednisolone is often favored over prolonged high-dose oral therapy for appropriate patients with active moderate-to-severe TED. Steroids tend to control inflammation better than they reverse established eye bulging or scar-related double vision.
Potential complications include high blood sugar, infection, mood changes, sleep disruption, elevated blood pressure, bone loss, stomach irritation, and liver problems. High-dose intravenous treatment requires careful screening and monitoring. Steroids are powerful tools, but they are not casual over-the-counter houseguests.
Teprotumumab
Teprotumumab-trbw, sold as Tepezza, is an intravenous insulin-like growth factor-1 receptor inhibitor approved in the United States for TED regardless of disease activity or duration. A standard course consists of eight infusions given three weeks apart.
Clinical trials found improvements in eye prominence, inflammation, double vision, and quality of life in many treated patients, although not everyone responds and symptoms can recur. Important risks include infusion reactions, elevated blood sugar, worsening inflammatory bowel disease, muscle spasms, and hearing impairment. Some hearing problems may be permanent, so hearing should be assessed before, during, and after therapy. The medication can harm a developing fetus, making pregnancy prevention and planning essential.
Veligrotug
In June 2026, the FDA approved veligrotug-vvze, sold as Lumvoa, as another IGF-1R-targeting treatment for thyroid eye disease. It is administered through five intravenous infusions over approximately 12 weeks and was studied in both active and chronic TED.
Because this therapy is newly approved, real-world availability, insurance requirements, infusion scheduling, and clinician experience may still be evolving. Patients considering either IGF-1R inhibitor should compare eligibility, expected benefits, monitoring needs, safety considerations, treatment duration, and out-of-pocket costs with a specialist.
Other immune-modifying medicines
Specialists may consider other medications when corticosteroids are ineffective, unsafe, or poorly tolerated. Options can include mycophenolate, rituximab, or tocilizumab. These drugs affect different parts of the immune response and are not interchangeable.
The evidence, availability, and preferred use of these therapies vary. Each may require laboratory testing and screening for infection or other health risks. Treatment is best directed by clinicians who regularly manage complex orbital inflammatory disease.
Orbital radiation therapy
Low-dose radiation directed at tissues behind the eyes may reduce inflammation and improve eye-movement problems in selected patients. It is sometimes combined with corticosteroids. Radiation is not the ideal choice for everyone and may be avoided or used cautiously in younger patients or people with certain retinal risks, uncontrolled diabetes, or severe hypertension.
How Is Sight-Threatening Thyroid Eye Disease Treated?
Sight-threatening TED demands immediate specialist care. One major complication is dysthyroid optic neuropathy, in which enlarged muscles or crowded tissues compress the optic nerve at the back of the eye socket. Severe corneal exposure can also damage the transparent surface of the eye.
Possible warning signs include declining visual sharpness, colors appearing faded, a new blind or blurry area, difficulty closing the eye, worsening eye pain, or a rapidly changing eye position. These symptoms should not wait for a convenient appointment next Thursday.
High-dose intravenous corticosteroids may be used urgently when optic nerve compression is suspected. If the response is insufficient, urgent orbital decompression surgery may be needed to create more room in the eye socket and relieve pressure. Corneal protection can require intensive lubrication, moisture chambers, temporary eyelid closure procedures, or surgery.
What Surgeries Are Used for Thyroid Eye Disease?
Except in emergencies, surgery is usually performed after TED has become inactive and thyroid levels are stable. Waiting helps surgeons work with tissues that are no longer changing from week to week.
Orbital decompression
Orbital decompression removes small amounts of bone, orbital fat, or both to enlarge the eye socket. It can reduce eye prominence, relieve pressure, improve eyelid closure, and protect the optic nerve. Risks include bleeding, sinus problems, numbness, asymmetry, and new or worsened double vision.
Strabismus surgery
TED can stiffen and scar the muscles that move the eyes, causing misalignment and double vision. Strabismus surgery adjusts these muscles to improve alignment, especially when looking straight ahead and downward. Prism glasses may still be needed afterward.
Eyelid surgery
Eyelid procedures may correct retraction, incomplete closure, puffiness, or changes in eyelid contour. They are generally performed after decompression and eye-muscle surgery because those procedures can alter the final eyelid position.
The usual surgical sequence is orbital decompression first, strabismus correction second, and eyelid repair last. Performing the steps in this order helps avoid undoing earlier work.
Thyroid Eye Disease Treatment FAQs
Will thyroid eye disease go away on its own?
The inflammatory phase often settles over time, especially in mild disease. However, bulging eyes, eyelid retraction, restricted movement, or double vision may remain after inflammation ends. “Inactive” does not necessarily mean “back to exactly how things were before.”
How quickly does treatment work?
Lubricating drops may provide relief within minutes, although they do not change the autoimmune process. Corticosteroids may reduce inflammatory symptoms over days or weeks. Targeted biologic therapy is evaluated over a course lasting several months. Surgical recovery varies according to the procedure and the person’s health.
Can TED return after treatment?
Yes. Some people experience recurrence or renewed activity after improvement. Others have persistent symptoms despite reduced inflammation. Regular follow-up helps identify changes early and allows the treatment plan to be adjusted.
Does everyone need surgery?
No. Many people with mild disease manage symptoms with lubrication, lifestyle changes, thyroid control, and monitoring. Surgery is considered when structural problems continue, vision is threatened, or symptoms significantly affect function or quality of life.
Can diet cure thyroid eye disease?
No specific diet has been shown to stop TED. Balanced nutrition supports general health, and reducing excessive sodium may help some people notice less puffiness. Supplements should not replace medical care, and megadoses can create entirely new problems that your eyes did not request.
Can I exercise during treatment?
Many people can continue moderate activity, but limitations depend on vision, balance, double vision, cardiovascular health, and the medicines being used. Avoid driving or hazardous activities when double vision is uncontrolled. Ask the treating team whether steroid therapy, surgery, or infusion treatment requires temporary adjustments.
Who should manage TED?
Care often works best when an endocrinologist collaborates with an ophthalmologist experienced in TED. Depending on the case, the team may also include an oculoplastic surgeon, neuro-ophthalmologist, strabismus surgeon, ear specialist, radiation oncologist, diabetes clinician, or smoking-cessation professional.
Will insurance cover newer treatments?
Coverage varies by insurer, diagnosis, disease severity, treatment history, and policy requirements. Biologic infusions frequently require prior authorization. Ask the clinic about benefit verification, appeals, manufacturer support programs, infusion-center charges, and expected personal costs before treatment begins.
Can TED be treated during pregnancy?
Pregnancy changes which medicines can be used safely. Teprotumumab can cause fetal harm and should not be used during pregnancy. Anyone who is pregnant, breastfeeding, or planning pregnancy should involve an obstetric clinician, endocrinologist, and eye specialist before starting systemic TED treatment.
What Thyroid Eye Disease Treatment Often Feels Like: A Composite Patient Journey
The following experience is a fictional composite based on common issues reported by people receiving TED care. It does not describe one identifiable patient and should not be interpreted as a guaranteed treatment course.
The first frustrating part of treatment is often figuring out which doctor owns the problem. A person may begin with an endocrinologist because blood tests show Graves’ disease. Then the eyes become dry and swollen, so an optometrist recommends lubricating drops. When double vision appears, an ophthalmologist enters the picture. Eventually, an orbital specialist explains that controlling thyroid hormones and treating the eyes are connected but separate jobs.
That explanation can bring relief. The symptoms are not imagined, and the person has not somehow failed thyroid treatment because the eyelids remain puffy. A structured examination measures visual sharpness, color vision, eye movement, eyelid closure, inflammation, and how far each eye protrudes. Photographs may be taken, and imaging may be ordered when optic nerve compression or another diagnosis must be ruled out.
For mild active disease, daily life may revolve around small adjustments. Artificial tears appear in coat pockets, desk drawers, and the mysterious compartment in the car that previously held only ancient receipts. Sunglasses reduce wind irritation. The head of the bed is raised. A prism is added to eyeglasses so that the laptop screen becomes one screen again rather than an unsolicited two-for-one promotion.
Smoking cessation may be the hardest recommendation, especially when stress is already high. Effective care treats quitting as medical therapy rather than a character test. Counseling and medication can make the process more manageable.
If symptoms progress, the conversation becomes more complicated. Corticosteroids may offer faster control of inflammation, but blood pressure, blood sugar, sleep, mood, and infection risk must be considered. Biologic infusion therapy may promise improvement in eye bulging or double vision, yet it also brings insurance paperwork, transportation planning, laboratory testing, hearing checks, and careful discussions about side effects.
Infusion days can be surprisingly ordinary. There may be a reclining chair, vital-sign checks, an IV line, snacks, and enough time to reconsider every life choice that led to forgetting headphones. Some people notice gradual improvement after several treatments; others do not see a dramatic difference. Photographs and measurements can reveal changes that are difficult to notice in the mirror from one day to the next.
Emotionally, TED treatment is not just about eyesight. Changes in facial appearance may affect confidence, work, social interaction, and willingness to be photographed. Double vision can reduce independence. Fatigue from Graves’ disease or medication can make appointments feel like a second job. A good care team asks about these effects instead of treating them as cosmetic footnotes.
When the active phase finally settles, the next decision may be whether to accept remaining changes or pursue surgery. Some people need decompression, eye-muscle surgery, and eyelid repair in stages. Others need only one procedureor none. Recovery requires patience because swelling can temporarily disguise the final result.
The most realistic version of success is not always a perfect return to the past. It may mean comfortable eyes, protected vision, manageable double vision, better eyelid closure, and a face that feels familiar again. Treatment is often a sequence of decisions rather than one dramatic fix, but steady specialist care can turn a chaotic condition into a manageable plan.
Conclusion
Thyroid eye disease treatment ranges from artificial tears and smoking cessation to corticosteroids, targeted IGF-1R medicines, radiation, and surgery. The best approach depends on whether TED is active, how severely it affects vision and quality of life, and which risks or medical conditions must be considered.
Early evaluation matters. Mild irritation may need simple protection and observation, while fading colors, declining vision, or severe corneal exposure may signal an emergency. Coordinated care from thyroid and eye specialists gives patients the best chance of controlling inflammation, protecting sight, and addressing the structural changes that remain.
Editorial research note: This article synthesizes current information from the U.S. Food and Drug Administration, National Eye Institute, American Thyroid Association, American Academy of Ophthalmology, Endocrine Society, Mayo Clinic, Cleveland Clinic, University of Michigan Health, UPMC, Stanford Health Care, University of Iowa Health Care, and peer-reviewed clinical consensus literature. Treatment recommendations and drug availability can change, particularly following recent FDA approvals.
